Study Visit Variable Statistic Group A
(Treatment naïve)
Group B
(Treatment experienced)
Total p-value
(N=155) (N=102) (N=257)
Persistence          
All Subjects Enrolled N 155 102 257  
  Never started treatment 1 N 9 (5.8%) 14 (13.7%) 23 (9.0%) -
30-Day Persistent Yes
No
132 (85.2%)
14 (9.0%)
82 (80.4%)
6 (5.9%)
214 (83.3%)
20 (7.8%)
.0720
Chi-Square test
90-Day Persistent Yes
No
126 (81.3%)
20 (12.9%)
76 (74.5%)
12 (11.8%)
202 (78.6%)
32 (12.5%)
.0937
Chi-Square test
All Subjects Starting Treatment 1 N 146 88 234 -
30-Day Persistent Yes
No
132 (90.4%)
14 (9.6%)
82 (93.2%)
6 (6.8%)
214 (91.5%)
20 (8.6%)
.4627
Chi-Square test
90-Day Persistent Yes
No
126 (86.3%)
20 (13.7%)
76 (86.4%)
12 (13.6%)
202 (86.3%)
32 (13.7%)
.9893
Chi-Square test
Compliance          
30-Day Percentage of days compliant N
M ± SD
Range
Mdn
134
95.3 ± 14.7
5, 100
100.0
79
96.5 ± 11.7
8, 100
100.0
213
95.7 ± 13.7
5, 100
100.0
.5307
Unpaired t-test
90-Day Percentage of days compliant N
M ± SD
Range
Mdn
121
97.2 ± 8.6
45, 100
100.0
75
97.6 ± 4.2
80, 100
100.0
196
97.4 ± 7.3
45, 100
100.0
.6707
Unpaired t-test
Table 3: Compliance and Persistence, M = Mean; SD = Standard Deviation; Mdn = Median; 1 Of the 257 subjects who were enrolled in this study, 23 subjects discontinued the study prior to starting glatiramer acetate treatment.